Back to All Events

2024 Arias Symposium: Bridging Basic Science and Liver Disease

33rd Annual Irwin M. Arias Symposium

The first Irwin M. Arias, M.D. Symposium was held in 1991, and the theme of the event was – as it remains today – Bridging Basic Science and Liver Disease.

This unique one-day program brings together hundreds of leading biomedical scientists and physicians from across the globe and is designed to bridge the remarkable advances in basic biology and engineering with the understanding of liver diseases and their treatment. Research presented over the past 33 years has led to advances in the diagnosis and treatment of virtually all liver diseases in children and adults.

With plenary talks from renowned researchers and a collection of three-minute micro talks delivered by trainee scientists, the Arias Symposium is a model in ‘bridging’ between the academic, industrial, and clinical research communities – even across disciplines.

The 2024 symposium will be offered both in-person and virtually. In-person attendees will benefit from a poster session and networking opportunities with plenary speakers and other attendees. Breakfast, lunch, and a networking reception will also be provided to in-person attendees. Registration is free for all trainees (postdocs, fellows, grad. students, undergrads, etc.). Registration is $50 for in-person attendees other than trainees. Virtual attendance is free but requires registration.

We welcome participation from researchers at every stage of their careers, and invite them to share perspectives from their academic, industrial, and clinical research settings. Trainees and early-career investigators who are interested in presenting a micro-talk (in-person or virtually) or poster (in-person only) should submit an abstract with their registration. The deadline to submit an abstract is November 1, 2024.

For queries related to Arias Symposium corporate sponsorship, please contact Heidi Daniels, HDaniels@liverfoundation.org.

Previous
Previous
November 7

Advancing Medical Applications of Cancer Nanotechnology at NCI/NCL

Next
Next
November 21

Doctor is In: Russ Jenkins MD, PhD: Patient-derived organotypic spheroids to study immunotherapy response